ReviewAllergy2018
Clinical trials in allergen immunotherapy: current concepts and future needs.
Review in Allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Molecular Aspects of Allergen-Specific Immunotherapy in Patients with Seasonal Allergic Rhinitis.Cells · 2023Pooled it
- Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.Allergy · 2025Trial
- The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach.Allergy · 2025Article
- Atopic dermatitis occurrence and progression and allergen immunotherapy: A real-world, retrospective cohort study in Germany.The World Allergy Organization journal · 2025Article
- AI-Driven Biomarker Discovery and Personalized Allergy Treatment: Utilizing Machine Learning and NGS.Current allergy and asthma reports · 2025Review
- House dust mite immunotherapy: A real-world, prescription data-based analysis.Clinical and translational allergy · 2024Article
- Clinical relevance of pre- and coseasonal sublingual immunotherapy with a 300 index of reactivity 5-grass SLIT tablet in allergic rhinoconjunctivitis.Clinical and translational allergy · 2023Article
- A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio.Clinical and translational allergy · 2023Article
- Persistence in allergen immunotherapy: A longitudinal, prescription data-based real-world analysis.Clinical and translational allergy · 2023Article
- Serological analysis of allergic components of house dust mite provides more insight in epidemiological characteristics and clinical symptom development in North China.Frontiers in immunology · 2023Article
- Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps.Allergologie select · 2023Review
- Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long-term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis.Clinical and translational allergy · 2022Article
- Efficacy and safety of house dust mite sublingual immunotherapy tablets in allergic rhinitis: A systematic review and meta-analysis.The World Allergy Organization journal · 2022Article
- Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model.Clinical and translational allergy · 2022Article
- Article
- Article
- Precision medicine reaching out to the patients in allergology - a German-Japanese workshop report.Allergologie select · 2021Article
- Allergen Immunotherapy: Biomarkers and Clinical Outcome Measures.Journal of asthma and allergy · 2021Review
- Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.Allergy · 2020Review
- Use of Sublingual Immunotherapy for Aeroallergens in Children with Asthma.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen immunotherapy (AIT) is a safe, effective treatment for allergic rhinoconjunctivitis and allergic asthma. However, AIT's clinical effect is still contested-primarily due to heterogeneity in clinical trial designs, study populations, therapeutic formulations, and efficacy criteria. After discussing current concepts and unmet needs, an international panel of experts made several recommendations: (i) explore and validate definitions for (clinical) responders in AIT trials; (ii) use of well-documented, standardized provocation tests prior to inclusion of subjects with relevant diseases in AIT trials; (iii) monitoring neo-sensitizations and occurrence of new allergy in extended AIT trials, and exclusion of polyallergic participants; (iv) validation of allergen exposure chambers with regard to natural exposure; (v) in studies of seasonal allergies, focus on peak exposure but also consider organizing two parallel, geographically distinct but otherwise identical trials; (vi) discuss adaptive trial designs with the regulatory authorities; (vii) use e-health and m-health technologies to capture more information on individual exposure to allergens; (viii) initiate research on potential psychological, biochemical, immune, neural, and even genomic markers of the placebo response; (ix) identify trial designs and primary endpoints that will give children with allergies easier, faster access to AIT formulations; and (x) promote and apply standardized methods for reporting systemic and local adverse events. The latest technologies and trial designs may provide novel, ethical ways of reducing bias and heterogeneity in AIT clinical trials. There is scope for physicians, patient organizations, companies, and regulators to improve clinical trials in AIT and, ultimately, to provide patients with better treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.